The complexity of modern cancer care, which spans surgery, systemic therapy, biomarker testing, supportive services, and social support, requires a level of interdependence across specialties that presents challenges for health care providers and patients alike. Delays or care breakdowns in the sequencing of any one element can have downstream consequences for a patient’s treatment trajectory, underscoring the need for structured, team-based approaches to oncology care delivery. In a recent article in the Journal of Clinical Oncology, Dr Julia Trosman and her colleagues evaluated whether implementation of the 4R Oncology Model, a systematic framework designed to establish high-functioning teams and optimize care timing and sequencing, could translate into measurable improvements in real-world practice for patients with lung and breast cancer. They found that with the implementation of this model, the timing and sequencing improved for all measured care types in both cancers, with 6 improvements reaching statistical significance.
The 4R model leverages principles from project management and team science to streamline how cancer care is planned, communicated, and optimized. At its core is a tool called the Care Sequence: a structured, modality-specific care plan that outlines guideline-based oncologic, supportive, and social care alongside the optimal timing and interdependencies of each component, from diagnosis through the full treatment continuum. Implementation of 4R occurs in 2 steps. In the first step, 4R Optimization, a multidisciplinary team collaboratively adapts Care Sequences to their institution’s conditions and agrees on timing and sequence of care. In the second step, 4R Clinical Use, these proposed optimizations are activated as clinicians begin using Care Sequences, personalized with individual patients at the point of care planning.
The study employed a quasi-experimental design, comparing care timing and sequencing between an intervention cohort of patients who were diagnosed post-4R, and a historical cohort who received standard care prior to 4R, at Kaiser Permanente Northern California. The lung cancer cohort included 138 post-4R intervention and 173 historical patients with lung cancer (any stage, non-small cell lung cancer), while the breast cancer cohort included 208 post-4R intervention and 268 historical patients with stage I to III breast cancer.
In lung cancer, the proportion of patients undergoing surgery within 10 weeks of an abnormal screening finding increased from 72% to 88% (P = .02), and the proportion with biomarker next-generation sequencing results available before their first medical oncology visit rose from 63% to 81% (P = .04).
In breast cancer, on-time gene expression profiling results improved from 34% to 70% (P <.001), and timely initiation of endocrine therapy increased from 78% to 89% (P = .03). The composite Optimization Index, a novel patient-level measure capturing the proportion of care delivered with optimized timing and sequencing, was significantly higher in the 4R cohorts compared with historical controls in both lung cancer (mean 0.82 vs 0.68; P <.001) and breast cancer (mean 0.81 vs 0.68; P <.001).
These findings carry meaningful implications for oncologists practicing in both academic and community settings. The 4R model implementation demonstrated that systematic, team-based approaches to care coordination can yield real and measurable improvements in the timeliness of guideline-recommended care. The authors acknowledge that gaps remain, including suboptimal performance of 4R among patients with lung cancer and high comorbidity burdens, and they emphasize that the framework is designed for iterative improvement over successive implementation cycles. Additional limitations of this study include the exclusion of patients with metastatic breast cancer and the possibility of residual confounding variables contributing to improvements in care over time. Moreover, the analysis focused on a single health care system, warranting further validation of 4R impact across additional clinics.
High level
This study raises important questions about the intersection of care delivery science and clinical outcomes research. Although systems might already be established at expert centers, the 4R model’s framework could be useful for streamlining such systems in the community setting. Moreover, the Optimization Index offers a novel, composite metric for quantifying interdependent care quality that could serve as a meaningful endpoint or stratification variable in future prospective trials examining the relationship between care coordination and survival, treatment adherence, or toxicity. Implementation of validated tools that standardize and measure care delivery quality alongside clinical endpoints could meaningfully reduce practice variation as a source of outcome heterogeneity. Indeed, a minimum cutoff value could be used to determine whether a center is a good candidate for expansion of a complex clinical trial. The authors’ observation that patients with high comorbidity burdens in lung cancer did not benefit to the same degree also warrants further investigation, as this subgroup is systematically underrepresented in clinical trials yet represents a substantial proportion of real-world oncology practice.
Ground level
The 4R Oncology Model significantly improved the timing and sequencing of interdependent cancer care for patients with lung and breast cancer in a community health system setting. Improvements were observed across both breast and lung cancers, with statistically significant gains in key areas, including surgical timing, biomarker result availability, and endocrine therapy initiation. For oncology teams in the community seeking practical strategies to reduce care delays and strengthen coordination, the 4R framework may be a useful tool for streamlining communication and referral policies.